http://medicalxpress.com/ en-us Medical Xpress internet news portal provides the latest news on Health and Medicine. Among patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) requiring hospital admission, a 5-day glucocorticoid treatment course was non-inferior (not worse than) to a 14-day course with regard to re-exacerbation during 6 months of follow-up, according to a study published online by JAMA. The study is being released early online to coincide with its presentation at the American Thoracic Society international conference. The authors write that these findings support a shorter-course glucocorticoid treatment regimen, which would reduce glucocorticoid exposure and the risk of possible adverse effects. http://medicalxpress.com/news/2013-05-shorter-duration-steroid-therapy-similar.html Diseases, Conditions, Syndromes Tue, 21 May 2013 15:18:08 EST news288368280 (Medical Xpress)—A new drug to prevent the early stages of Alzheimer's disease could enter clinical trials in a few years' time according to scientists. http://medicalxpress.com/news/2013-02-treatment-alzheimer-disease-closer.html Alzheimer's disease & dementia Fri, 01 Feb 2013 10:19:54 EST news278936387 (HealthDay)—A phase I trial of dasatinib combined with paclitaxel and carboplatin has determined the optimal dose of dasatinib and suggested some efficacy in women with advanced or recurrent ovarian cancer, according to research published in the Oct. 1 issue of Clinical Cancer Research. http://medicalxpress.com/news/2012-11-optimal-dose-dasatinib-ovarian-cancer.html Cancer Mon, 19 Nov 2012 10:00:13 EST news272540632 About half of all people with cancer receive a course of radiotherapy, a form of treatment in which X-rays are used to shrink or destroy the tumour. With the benefit of advanced systems, it is now possible to aim radiation beams at tumours more effectively than ever before, allowing increasing doses of radiotherapy with increased cancer cure rates, and also reducing side effects. http://medicalxpress.com/news/2012-10-methods-radiotherapy-tissue.html Cancer Mon, 01 Oct 2012 08:27:05 EST news268298815 (Medical Xpress)—Researchers at University of California, San Diego Moores Cancer Center are evaluating the safety and tolerability of a synthetic cannabinoid called dexanabinol (ETS2101). Delivered as a weekly intravenous infusion, the drug is being tested in patients with all forms of brain cancer, both primary and metastatic. http://medicalxpress.com/news/2012-09-clinical-trial-synthetic-cannabinoid-brain.html Cancer Wed, 26 Sep 2012 09:27:19 EST news267870387